Group 3 Pulmonary Hypertension: From Bench to Bedside

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2022 Apr 28

PMID 35482836

Authors

Navneet Singh

Peter Dorfmuller

Oksana A Shlobin

Corey E Ventetuolo

Affiliations

Soon will be listed here.

Abstract

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.

Citing Articles

Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment.

Park J, Choi Y, Min J, Lee J, Shim G Pharmaceutics. 2025; 17(2).

PMID: 40006591 PMC: 11859843. DOI: 10.3390/pharmaceutics17020224.

Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.

Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K Int J Mol Sci. 2025; 26(2).

PMID: 39859549 PMC: 11765551. DOI: 10.3390/ijms26020835.

Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.

Nathan S, Stinchon Jr M, Atcheson S, Simone L, Nelson M J Manag Care Spec Pharm. 2025; 31(1-a Suppl):S2-S17.

PMID: 39745852 PMC: 11695281. DOI: 10.18553/jmcp.2025.31.1-a.s2.

PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling and .

Lin J, Pan Z, Sun J, Wang X, Yin D, Huo C Front Med (Lausanne). 2024; 11:1509168.

PMID: 39722825 PMC: 11668660. DOI: 10.3389/fmed.2024.1509168.

Mechanisms Controlling the Behavior of Vascular Smooth Muscle Cells in Hypoxic Pulmonary Hypertension.

Bacakova L, Sedlar A, Musilkova J, Eckhardt A, Zaloudikova M, Kolar F Physiol Res. 2024; 73(S2):S569-S596.

PMID: 39589304 PMC: 11627264.

References

Nathan S, Tapson V, Elwing J, Rischard F, Mehta J, Shapiro S . Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. Am J Respir Crit Care Med. 2021; 205(2):198-207. PMC: 8787243. DOI: 10.1164/rccm.202107-1766OC. View

Alkukhun L, Wang X, Ahmed M, Baumgartner M, Budev M, Dweik R . Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2016; 117:65-72. PMC: 4976395. DOI: 10.1016/j.rmed.2016.06.001. View

Wadhawan R, Vohr B, Fanaroff A, Perritt R, Duara S, Stoll B . Does labor influence neonatal and neurodevelopmental outcomes of extremely-low-birth-weight infants who are born by cesarean delivery?. Am J Obstet Gynecol. 2003; 189(2):501-6. DOI: 10.1067/s0002-9378(03)00360-0. View

Santos S, Peinado V, Ramirez J, Morales-Blanhir J, Bastos R, Roca J . Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167(9):1250-6. DOI: 10.1164/rccm.200210-1233OC. View

Leifer F, Konicek D, Chen K, Plaunt A, Salvail D, Laurent C . Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation. Drug Res (Stuttg). 2018; 68(11):605-614. DOI: 10.1055/s-0044-100374. View

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View

Leuchte H, Baumgartner R, El Nounou M, Vogeser M, Neurohr C, Trautnitz M . Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006; 173(7):744-50. DOI: 10.1164/rccm.200510-1545OC. View

Nathan S, Waxman A, Rajagopal S, Case A, Johri S, Dubrock H . Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021; 9(11):1266-1274. DOI: 10.1016/S2213-2600(21)00165-X. View

Bogaard H, Abe K, Vonk Noordegraaf A, Voelkel N . The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009; 135(3):794-804. DOI: 10.1378/chest.08-0492. View

10.

Prins K, Rose L, Archer S, Pritzker M, Weir E, Kazmirczak F . Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. Am J Respir Crit Care Med. 2018; 197(11):1496-1499. PMC: 6005552. DOI: 10.1164/rccm.201712-2405LE. View

11.

Gore B, Izikki M, Mercier O, Dewachter L, Fadel E, Humbert M . Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. PLoS One. 2014; 9(6):e100310. PMC: 4067299. DOI: 10.1371/journal.pone.0100310. View

12.

Swigris J, Olson A, Shlobin O, Ahmad S, Brown K, Nathan S . Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2010; 16(3):439-45. PMC: 3753822. DOI: 10.1111/j.1440-1843.2010.01877.x. View

13.

Abe K, Toba M, Alzoubi A, Ito M, Fagan K, Cool C . Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010; 121(25):2747-54. DOI: 10.1161/CIRCULATIONAHA.109.927681. View

14.

Masa J, Corral J, Caballero C, Barrot E, Teran-Santos J, Alonso-Alvarez M . Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax. 2016; 71(10):899-906. PMC: 5036235. DOI: 10.1136/thoraxjnl-2016-208501. View

15.

Carlsen J, Andersen K, Boesgaard S, Iversen M, Steinbruchel D, Andersen C . Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012; 32(3):347-54. DOI: 10.1016/j.healun.2012.11.014. View

16.

Murakami S, Nagaya N, Itoh T, Kataoka M, Iwase T, Horio T . Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2005; 290(1):L59-65. DOI: 10.1152/ajplung.00042.2005. View

17.

. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020; 8(6):585-596. PMC: 7284317. DOI: 10.1016/S2213-2600(20)30105-3. View

18.

Mathai S, Puhan M, Lam D, Wise R . The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186(5):428-33. PMC: 3443803. DOI: 10.1164/rccm.201203-0480OC. View

19.

Buda A, Pinsky M, Ingels Jr N, Daughters 2nd G, Stinson E, Alderman E . Effect of intrathoracic pressure on left ventricular performance. N Engl J Med. 1979; 301(9):453-9. DOI: 10.1056/NEJM197908303010901. View

20.

Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C . Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995; 107(5):1193-8. DOI: 10.1378/chest.107.5.1193. View